EFFECTS OF HM15211, A NOVEL LONG-ACTING GLUCAGON/GIP/GLP-1 TRIPLE AGONIST, ON ANTI-INFLAMMATION AND ANTI-FIBROSIS IN TAA-INDUCED MOUSE MODEL OF LIVER INJURY AND FIBROSIS

被引：0
|
作者：
Kwon, Hyunjoo [1 ]
Kim, Jung Kuk [1 ]
Lee, Jong Suk [1 ]
Kim, Yohan [1 ]
Park, Eun Jin [1 ]
Choi, Jaehyuk [2 ]
Bae, Sung Min [1 ]
Kim, Dae Jin [1 ]
Lee, Sang Hyun [1 ]
Choi, In Young [1 ]
机构：
[1] Hanmi Pharm Co Ltd, Seoul, South Korea
[2] 14 Wiryeseong Daero, Wiryeseong Daero, South Korea
来源：
HEPATOLOGY | 2022年 / 76卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
2453
引用
收藏
页码：S716 / S717
页数：2
相关论文
共 50 条
  • [41] Potent Body Weight Loss and Efficacy in a NASH Animal Model by a Novel Long-Acting GLP-1/Glucagon/GIP Tri-Agonist (HM15211)
    Choi, In Young
    Lee, Jong Suk
    Kim, Jung Kuk
    Park, Young Jin
    Jung, Sungyoub
    Kim, Young Hoon
    Kwon, Se Chang
    DIABETES, 2017, 66 : A304 - A304
  • [42] Therapeutic effect of a novel long-actingGLP-1/GIP/Glucagon triple agonist (HM15211) in CDHFD-induced NASH and fibrosis mice
    Choi, J.
    Jo, H.
    Kim, J.
    Kwon, H.
    Lee, J.
    Bae, S.
    Kim, D.
    Lee, S.
    Choi, I.
    DIABETOLOGIA, 2020, 63 (SUPPL 1) : S64 - S64
  • [43] Multitarget Engagement Effect of a Novel Long-Acting Glucagon/GIPIGLP-1 Triple Agonist (HM15211) in Animal Model of NASH
    Kim, Jung Kuk
    Lee, Jong Suk
    Kwon, Hyunjoo
    Park, Eunjin
    Lee, Jongsoo
    Bae, Sungmin
    Lee, Sang Hyun
    Choi, In Young
    DIABETES, 2021, 70
  • [44] Potent body weight loss, and therapeutic efficacy in a NASH animal model by a novel long-acting GLP-1/Glucagon/GIPtri-agonist (HM15211)
    Choi, I.
    Lee, J.
    Kim, J.
    Park, Y.
    Lee, S.
    Kim, Y.
    Kwon, S. -C.
    DIABETOLOGIA, 2017, 60 : S50 - S50
  • [45] Novel Combination of a Long-Acting GLP-1/GIP/Glucagon Triple Agonist (HM15211) and Once-Weekly Basal Insulin (HM12460a) Offers Improved Glucose Lowering and Weight Loss in a Diabetic Animal Model
    Kim, Jung Kuk
    Lee, Jong Suk
    Choi, Jaehyuk
    Jung, Sung Youb
    Lee, Sang Hyun
    Choi, In Young
    Kim, Sun Jin
    DIABETES, 2018, 67
  • [46] A randomized, double-blinded, placebo-controlled single ascending dose study to assess safety, tolerability, immunogenicity, and pharmacokinetics of a novel long-acting GLP-1/GIP/glucagon triple agonist (hm15211) in healthy obese subjects
    Choi, JaeDuk
    Kim, Youngmin
    Eun, Kahee
    Morrow, Linda
    Hompesch, Marcus
    Baek, Seungjae
    JOURNAL OF HEPATOLOGY, 2020, 73 : S455 - S456
  • [47] Lipolytic and insulinotropic effects of HM12525A, a novel long-acting GLP-1/glucagon dual agonist
    Jung, S.
    Park, Y.
    Kim, J.
    Lee, J.
    Lee, Y. -M.
    Kim, Y.
    Kang, J.
    Trautmann, M.
    Hompesch, M.
    Kwon, S.
    DIABETOLOGIA, 2014, 57 : S352 - S352
  • [48] Potential Cardioprotective Effects of HM15275, a Novel, Long-Acting GLP-1/GIP/GCG Triple Agonist, in Animal Models of Hypertension
    Lee, Seon Myeong
    Kim, Jung Kuk
    Park, Eunjin
    Kang, Hye Reyeon
    Kim, Jeong A.
    Kim, Yohan
    Hong, Sunghee
    Bae, Sungmin
    Lee, Sang Hyun
    Choi, In Young
    DIABETES, 2024, 73
  • [49] A Double-Blinded, Placebo Controlled, Single Ascending Dose Study for Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics after Subcutaneous Administration of Novel Long-Acting GLP-1/GIP/Glucagon Triple Agonist (HM15211) in Healthy Obese Subjects
    Choi, Jae Duk
    Baek, Seungjae
    Kim, Youngmin
    Eun, Kahee
    Kwon, Se Chang
    Morrow, Linda
    Hompesch, Marcus
    Kang, Jahoon
    DIABETES, 2019, 68
  • [50] Therapeutic Potential of HM15275, a Novel Long-Acting GLP-1/GIP/GCG Triple Agonist, in Animal Models of Heart Failure
    Ye, Byeongjin
    Kim, Wonki
    Lee, Seon Myeong
    Kim, Jeong A.
    Kim, Eunseon
    Bae, Sungmin
    Lee, Sang Hyun
    Choi, In Young
    DIABETES, 2024, 73
12345